Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis

Hepatology

Volumn 60, Issue 3, 2014, Pages 931-940

  Wunsch, Ewa ^a   Trottier, Jocelyn ^b   Milkiewicz, Malgorzata ^a   Raszeja Wyszomirska, Joanna ^a,c   Hirschfield, Gideon M ^d   Barbier, Olivier ^b   Milkiewicz, Piotr ^a,c  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b LAVAL UNIVERSITY   (Canada)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHENODEOXYCHOLIC ACID; CHOLIC ACID; DEOXYCHOLIC ACID; FIBROBLAST GROWTH FACTOR 19; GAMMA GLUTAMYLTRANSFERASE; GLYCINE; HYODEOXYCHOLIC ACID; LITHOCHOLIC ACID; TAURINE; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE ACID BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DETERIORATION; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIQUID CHROMATOGRAPHY; MALE; MAYO RISK SCORE; PATIENT ASSESSMENT; PBC 40; PLASMA; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SHORT FORM 36; TANDEM MASS SPECTROMETRY;

ADULT; ALKALINE PHOSPHATASE; BILE ACIDS AND SALTS; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; LIVER FUNCTION TESTS; MALE; PROSPECTIVE STUDIES; PRURITUS; QUALITY OF LIFE; URSODEOXYCHOLIC ACID; YOUNG ADULT;

EID: 84906794957     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27074     Document Type: Article

References (49)

1. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet 2013;382:1587-1599.
2. Milkiewicz P, Wunsch E, Elias E. Liver transplantation in chronic cholestatic conditions. Front Biosci 2012;17:959-969.
3. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 2001;35:134-146.
4. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-890.
5. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology 2009;50:291-308.
6. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-814.
7. Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? Hepatology 2009;50:671-673.
8. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-678.
9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-267.
10. Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009;49:1228-1235.
11. Zhang JH, Nolan JD, Kennie SL, Johnston IM, Dew T, Dixon PH, et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol 2013;304:G940-G948.
12. Trottier J, Perreault M, Rudkowska I, Levy C, Dallaire-Theroux A, Verreault M, et al. Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants and response to fenofibrate. Clin Pharmacol Ther 2013;94:533-543.
13. Trottier J, Caron P, Straka RJ, Barbier O. Profile of serum bile acids in noncholestatic volunteers: gender-related differences in response to fenofibrate. Clin Pharmacol Ther 2011;90:279-286.
14. Trottier J, Bialek A, Caron P, Straka RJ, Milkiewicz P, Barbier O. Profiling circulating and urinary bile acids in patients with biliary obstruction before and after biliary stenting. PLoS One 2011;6:e22094.
15. Trottier J, Bialek A, Caron P, Straka RJ, Heathcote J, Milkiewicz P, et al. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Dig Liver Dis 2012;44:303-310.
16. Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012;92:502-507.
17. Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James OF, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut 2005;54:1622-1629.
18. Al-Harthy N, Kumagi T, Parasar S, Coltescu C, Heathcote EJ, Hirschfield GM. High prevalence of fatigue in patients with sclerosing cholangitis [abstract]. J Hepatol 2009;50(Suppl 1):S241.
19. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483.
20. Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000;75:688-694.
21. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992;16:707-714.
22. Chazouilleres O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990;11:120-123.
23. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-1290.
24. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691-695.
25. Mitchell SA, Bansi DS, Hunt N, Von BK, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-907.
26. Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013;58:329-334.
27. Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: relation to disease progression. Hepatology 2010;52:197-203.
28. Dilger K, Hohenester S, Winkler-Budenhofer U, Bastiaansen BA, Schaap FG, Rust C, et al. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol 2012;57:133-140.
29. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004;40:693-698.
30. Batta AK, Salen G, Arora R, Shefer S, Tint GS, Abroon J, et al. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology 1989;10:414-419.
31. Crosignani A, Podda M, Battezzati PM, Bertolini E, Zuin M, Watson D, et al. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991;14:1000-1007.
32. Rudolph G, Kloeters-Plachky P, Sauer P, Stiehl A. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate. Eur J Clin Invest 2002;32:575-580.
33. Stiehl A, Raedsch R, Rudolph G. Ileal excretion of bile acids: comparison with biliary bile composition and effect of ursodeoxycholic acid treatment. Gastroenterology 1988;94:1201-1206.
34. Radominska A, Treat S, Little J. Bile acid metabolism and the pathophysiology of cholestasis. Semin Liver Dis 1993;13:219-234.
35. Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R, et al. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol 2006;168:410-422.
36. Kozoni V, Tsioulias G, Shiff S, Rigas B. The effect of lithocholic acid on proliferation and apoptosis during the early stages of colon carcinogenesis: differential effect on apoptosis in the presence of a colon carcinogen. Carcinogenesis 2000;21:999-1005.
37. Nagengast FM, Grubben MJ, van Munster IP. Role of bile acids in colorectal carcinogenesis. Eur J Cancer 1995;31A:1067-1070.
38. Reddy BS, Watanabe K. Effect of cholesterol metabolites and promoting effect of lithocholic acid in colon carcinogenesis in germ-free and conventional F344 rats. Cancer Res 1979;39:1521-1524.
39. Alnouti Y. Bile Acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol Sci 2009;108:225-246.
40. Gadacz TR, Allan RN, Mack E, Hofmann AF. Impaired lithocholate sulfation in the rhesus monkey: a possible mechanism for chenodeoxycholate toxicity. Gastroenterology 1976;70:1125-1129.
41. Hofmann AF. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab Rev 2004;36:703-722.
42. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-253.
43. Choi M, Moschetta A, Bookout AL, Peng L, Umetani M, Holmstrom SR, et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006;12:1253-1255.
44. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004;145:2594-2603.
45. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002;143:1741-1747.
46. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003;17:1581-1591.
47. Lin BC, Wang M, Blackmore C, Desnoyers LR. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 2007;282:27277-27284.
48. Wu AL, Coulter S, Liddle C, Wong A, Eastham-Anderson J, French DM, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One 2011;6:e17868.
49. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-1472.